Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-02
DOI
10.3389/fimmu.2022.801909
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
- (2021) Hong Zong et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
- (2021) Alessandro Rizzo et al. Cancers
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
- (2021) Angela Lamarca et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
- (2021) Shukui Qin et al. Liver Cancer
- The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
- (2021) Dongxu Wang et al. Frontiers in Oncology
- A phase Ib study of anlotinib plus TQB2450 as second-line therapy for advanced biliary tract adenocarcinoma.
- (2021) Yongkun Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.
- (2021) Sophie Cousin et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- Pd-1 inhibitors plus nab-paclitaxel with S1 (AS) as first line in patients with advanced biliary tract cancer.
- (2020) Miaomiao Gou et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).
- (2020) Do-Youn Oh et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
- (2020) Naiyer A. Rizvi et al. JAMA Oncology
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- The Tumor Microenvironment in Cholangiocarcinoma Progression
- (2020) Luca Fabris et al. HEPATOLOGY
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
- (2020) Oliver Klein et al. JAMA Oncology
- Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
- (2020) Sang Hoon Lee et al. Journal of Clinical Medicine
- Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
- (2020) Jianzhen Lin et al. Hepatobiliary Surgery and Nutrition
- 53P Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: A preliminary analysis of safety and efficacy of an open-label phase II clinical study
- (2020) T. Liu et al. ANNALS OF ONCOLOGY
- Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
- (2020) Angela Dalia Ricci et al. Cancer Control
- Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
- (2020) Alice Boilève et al. EUROPEAN JOURNAL OF CANCER
- Recent advances of immunotherapy for biliary tract cancer
- (2020) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
- (2019) Charalampos S. Floudas et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
- (2019) Dongxu Wang et al. Journal of Hematology & Oncology
- Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
- (2019) Danyang Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
- (2019) Junho Kang et al. Cancer Research and Treatment
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Burden of Liver Diseases in the World
- (2018) Sumeet K. Asrani et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Global epidemiological trends and variations in the burden of gallbladder cancer
- (2017) Chandrakanth Are et al. JOURNAL OF SURGICAL ONCOLOGY
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects
- (2014) Christophe Combescure et al. STATISTICS IN MEDICINE
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
- (2013) D Sia et al. ONCOGENE
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
- (2011) W. Joost Lesterhuis et al. JOURNAL OF CLINICAL INVESTIGATION
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion
- (2009) Yufu Ye et al. JOURNAL OF SURGICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation